Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 4, 2001, Pages 266-273

  Yu, Kyung Sang ^a,b,c   Yim, Dong Seok ^a,b,c   Cho, Joo Youn ^a,b,c   Park, Soon Seong ^a,b,c   Park, Ji Young ^a,b,c   Lee, Kyung Hoon ^a,b,c   Jang, In Jin ^a,b,c   Yi, So Young ^a,b,c   Bae, Kyun Seop ^a,b,c   Shin, Sang Goo ^a,b,c  

^a Seoul National University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (4 CHLOROBENZAMIDO)ETHYL]MORPHOLINE 4 OXIDE; 4 CHLORO N [2 (3 OXOMORPHOLINO)ETHYL]BENZAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE; MOCLOBEMIDE; OMEPRAZOLE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME INHIBITION; ENZYME POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZAMIDES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; MOCLOBEMIDE; MORPHOLINES; OMEPRAZOLE; POLYMORPHISM, GENETIC; RANDOM ALLOCATION;

EID: 0035029870     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.114231     Document Type: Article

References (30)

1. Moclobemide, an update of its pharmacological properties and therapeutic use
2. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide
3. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study
4. Clinical overview on moclobemide
5. Pharmacology of moclobemide
6. Biotransformation of moclobemide in humans
7. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
8. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status
9. Genetic polymorphism of S-mephenytoin 4′-hydroxylation
10. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
11. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
12. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
13. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
14. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
15. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
16. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
17. Pharmacogenetics in clinical pharmacology and toxicology
18. Geographical/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
19. Drug interactions and the cytochrome P450 system: The role of cytochrome P450 2C19
20. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole
21. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole
22. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
23. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide
24. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole and pantoprazole
25. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography
26. Branch propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities
27. Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine
28. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe
29. Genetic polymorphism of Smephenytoin 4′-hydroxylation in African-Americans